Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Six Questions For TB Alliance CEO On Pretomanid And Pricing Issues

Executive Summary

TB Alliance CEO Mel Spigelman outlines to Scrip the contours of the non-profit’s commercialization deal with Mylan for pretomanid, which is part of an oral combination regimen, and maintains that the $1/day pricing ask for the drug is based on flawed assumptions and not currently feasible.

You may also be interested in...



Pretomanid Price Cut By 34% But Access Complexities Remain

Viatris, MedAccess and TB Alliance deal to lower the price of pretomanid, a key drug used as part of a shorter all-oral drug regime for multidrug-resistant TB, but country-level prioritization and uptake of the treatment option will be pivotal to widen access sharply.

Pharma, Non-Profits Ally To Advance TB Drug Combinations

The Project to Accelerate New Treatments for Tuberculosis (PAN-TB) is pulling together philanthropic, non-profit and private sector participants to collaboratively run Phase II trials for five drugs from Janssen, Otsuka, the TB Alliance and the Bill & Melinda Gates Medical Research Institute.

TB Alliance CEO On Less Toxic Treatment Regimens, Pretomanid Plans

TB Alliance CEO Mel Spigelman discusses a range of new and evolving aspects pertaining to the three-drug BPaL regimen for highly drug-resistant TB, including the ZeNix trial results and adding a licensee for pretomanid. He also notes how COVID-19 has had a “terrible impact” on efforts to tackle the TB pandemic.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC126177

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel